Applicability and procedural success rate of bioresorbable vascular scaffolds for percutaneous coronary intervention in an all-comer cohort of 383 consecutive patients
暂无分享,去创建一个
S. Achenbach | M. Marwan | C. Schlundt | H. Nef | J. Ludwig | M. Tröbs | Fabiola Felten | J. Roether
[1] S. Achenbach,et al. Bioresorbable vascular scaffold thrombosis in a consecutive cohort of 550 patients , 2016, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[2] S. Ooi,et al. Twelve-Month Outcomes With a Bioresorbable Everolimus-Eluting Scaffold: Results of the ESHC-BVS Registry at Two Australian Centers. , 2016, The Journal of invasive cardiology.
[3] W. Cheong,et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. , 2015, European heart journal.
[4] W. Cheong,et al. Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial. , 2015, Journal of the American College of Cardiology.
[5] P. Teirstein,et al. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. , 2015, The New England journal of medicine.
[6] J. Brachmann,et al. Beyond the early stages: insights from the ASSURE registry on bioresorbable vascular scaffolds. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[7] R. Whitbourn,et al. Impact of post-dilation on the acute and one-year clinical outcomes of a large cohort of patients treated solely with the Absorb Bioresorbable Vascular Scaffold. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[8] M. Togni,et al. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. , 2015, Journal of the American College of Cardiology.
[9] A. Colombo,et al. Procedural feasibility and clinical outcomes in propensity-matched patients treated with bioresorbable scaffolds vs new-generation drug-eluting stents. , 2015, The Canadian journal of cardiology.
[10] M. Valgimigli,et al. Current know how on the absorb BVS technology: an experts' survey. , 2015, International journal of cardiology.
[11] Antonio Colombo,et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[12] P. Serruys,et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial , 2015, The Lancet.
[13] A. Colombo,et al. Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus‐eluting stent implantation in a real‐world population , 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[14] J. Reiber,et al. Is it safe to implant bioresorbable scaffolds in ostial side-branch lesions? Impact of 'neo-carina' formation on main-branch flow pattern. Longitudinal clinical observations. , 2015, Atherosclerosis.
[15] C. Hamm,et al. Current status of bioresorbable scaffolds in the treatment of coronary artery disease. , 2014, Journal of the American College of Cardiology.
[16] T. Lüscher,et al. Feasibility of second-generation bioresorbable vascular scaffold implantation in complex anatomical and clinical scenarios , 2014, Clinical Research in Cardiology.
[17] P. Serruys,et al. Procedural and clinical outcomes of the Absorb everolimus-eluting bioresorbable vascular scaffold: one-month results of the Bioresorbable vascular Scaffold Evaluated At Rotterdam Cardiology Hospitals (B-SEARCH). , 2014, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[18] D. Capodanno,et al. Treatment of coronary bifurcation lesions with bioresorbable vascular scaffolds. , 2014, Minerva cardioangiologica.
[19] A. Colombo,et al. The absorb bioresorbable vascular scaffold in coronary bifurcations: insights from bench testing. , 2014, JACC. Cardiovascular interventions.
[20] P. Serruys,et al. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. , 2013, JACC. Cardiovascular interventions.
[21] P. Serruys,et al. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease c , 2012, American heart journal.
[22] Patrick W Serruys,et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial , 2008, The Lancet.
[23] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[24] F. Burzotta,et al. Comparison of outcomes (early and six- month) of direct stenting with conventional stenting (a meta-analysis of ten randomized trials). , 2003, The American journal of cardiology.
[25] H. Uehata,et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. , 2000, Circulation.
[26] F. Loop,et al. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). , 1988, Circulation.